(Q38105970)

28 August 2017

title

Immune-suppressive properties of the tumor microenvironment (English)

1 reference

28 August 2017

2

Mads Hald Andersen

1 reference

28 August 2017

4

Per Thor Straten

1 reference

28 August 2017

1

Jürgen C Becker

1 reference

28 August 2017

David Schrama

3

1 reference

28 August 2017

publication date

11 May 2013

1 reference

Cancer Immunology, Immunotherapy

28 August 2017

published in

1 reference

28 August 2017

volume

62

1 reference

28 August 2017

issue

7

1 reference

28 August 2017

page(s)

1137-1148

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-013-1434-6

28 August 2017

exact match

0 references

cites work

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Hallmarks of cancer: interactions with the tumor stroma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

21 January 2018

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Tumors as organs: complex tissues that interface with the entire organism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Raising the bar: the curative potential of human cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Cellular constituents of immune escape within the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Suppressive influences in the immune response to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Endogenous modulators of inflammatory cell recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

The yin-yang of tumor-associated neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Tissue-based class control: the other side of tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Role of matrix metalloproteinases in melanoma cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

ADAM17: a molecular switch to control inflammation and tissue regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

T(H)17 cells in tumour immunity and immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

IDO is a nodal pathogenic driver of lung cancer and metastasis development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Tryptophan hydroxylase-1 regulates immune tolerance and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Regulation of immune responses by L-arginine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

The role of the EP receptors for prostaglandin E2 in skin and skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Hypoxia promotes tumor growth in linking angiogenesis to immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Nitric oxide and redox mechanisms in the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Suppression of T-cell responses by tumor metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Lactate: a metabolic key player in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Extracellular adenosine triphosphate and adenosine in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Adenosine receptors: therapeutic aspects for inflammatory and immune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Receptor desensitization and blockade of the suppressive effects of prostaglandin E(2) and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

CD73: a potent suppressor of antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Beyond ipilimumab: new approaches target the immunological synapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Ipilimumab: first global approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Immunologic correlates of the abscopal effect in a patient with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

A landscape of driver mutations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Immunoregulatory molecules are master regulators of inflammation during the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

The expression, function, and clinical relevance of B7 family members in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Fine tuning the immune response through B7-H3 and B7-H4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Effect of NKG2D ligand expression on host immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Tumor-associated MICA is shed by ADAM proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: role of nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Expression, signaling proficiency, and stimulatory function of the NKG2D lymphocyte receptor in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Quantitation of peroxidase-antibody binding to membrane fragments using column chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Recent advances on the role of tumor exosomes in immunosuppression and disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

More insights into the immunosuppressive potential of tumor exosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Induction of myeloid-derived suppressor cells by tumor exosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

An immune-active tumor microenvironment favors clinical response to ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1434-6

10.1007/S00262-013-1434-6

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1004066632

0 references

1 reference